{"filings":[{"id":97153,"accession_number":"0000200406-26-000089","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"JNJ shareholders elect all 12 directors, approve say-on-pay, reject independent chair proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected with strong support (over 1.65B shares for each).","Advisory say-on-pay approved with ~94.5% of votes cast in favor (1.64B for, 91.8M against).","Ratification of PwC as auditor for 2026 passed with ~93% of votes cast (1.91B for, 138.6M against).","Shareholder proposal for independent board chair defeated with ~76.6% against (1.33B against vs 406M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97152,"accession_number":"0000200406-26-000076","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"JNJ Q1 adj. EPS $2.70 (down 1.4% YoY); raises dividend 3.1% to $1.34/qtr","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $24.06B, up 9.9% YoY (operational growth 6.4%, currency 3.5%).","GAAP net earnings $5.24B ($2.14 diluted EPS) vs $11.0B ($4.54) in Q1 2025, down 52% due to prior-year other income.","Adjusted net earnings $6.61B ($2.70 diluted EPS) vs $6.71B ($2.77), down 1.4% YoY.","Dividend increased 3.1% to $1.34 per quarter ($5.36 annual), marking 64th consecutive annual increase; payable June 9, 2026 to record May 26.","Innovative Medicine segment sales $15.4B (+11.2%); MedTech $8.6B (+7.7%)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":24062000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111698,"accession_number":"0000200406-26-000002","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q4 2025 sales $24.6B (+9.1% YoY), net earnings $5.1B ($2.10 EPS); adj. EPS $2.46","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $24,564M (+9.1% YoY); full-year sales $94,193M (+6.0% YoY).","Q4 net earnings $5,116M ($2.10 diluted EPS) vs $3,431M ($1.41) a year ago.","Adjusted Q4 net earnings $6,009M ($2.46 adj. diluted EPS) vs $4,946M ($2.04).","R&D expense decreased 19.7% YoY to $4,252M; effective tax rate was -3.0%.","MedTech segment sales $8,801M (+7.5% YoY); Innovative Medicine $15,763M (+10.0% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":11.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":94193000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128330,"accession_number":"0000200406-25-000201","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"JNJ reports Q3 adjusted EPS $2.80; plans to spin off Orthopaedics as DePuy Synthes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 revenue $23,993M (+6.8% YoY); GAAP EPS $2.12, adjusted EPS $2.80 (+15.7% YoY).","Innovative Medicine sales $15,563M (+6.8% operational); MedTech sales $8,430M (+6.8% operational).","Intends to separate Orthopaedics business into standalone DePuy Synthes; FY2024 ortho sales ~$9.2B.","Target completion in 18-24 months; Namal Nawana appointed Worldwide President of DePuy Synthes.","Separation aims to shift MedTech portfolio to higher-growth/margin markets; JNJ retains focus on six growth areas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145135,"accession_number":"0000200406-25-000190","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Johnson & Johnson elects John Morikis to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Morikis elected to JNJ Board effective Sept. 8, 2025; will serve on Audit and Compensation Committees.","Morikis was Executive Chairman, President & CEO of Sherwin-Williams from 2016 to 2024.","He joined Sherwin-Williams in 1984 and served as President & COO from 2006-2016.","As non-employee director, he will receive standard director compensation per 2025 Proxy Statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145134,"accession_number":"0000200406-25-000170","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q2 sales $23.7B (+5.8%); GAAP EPS $2.29 (+18.7%); adj. EPS $2.77 (-1.8%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 sales $23,743M (+5.8% YoY); U.S. $13,544M (+7.8%), International $10,199M (+3.2%).","GAAP net earnings $5,537M; diluted EPS $2.29 vs $1.93 a year ago (+18.7%).","Adjusted net earnings $6,699M; adjusted diluted EPS $2.77 vs $2.82 (-1.8%).","Innovative Medicine sales $15,202M (+4.9%); MedTech sales $8,541M (+7.3%).","Gross margin 67.9% vs 69.4% year ago; R&D expense $3,516M (14.8% of sales)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":45636000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163525,"accession_number":"0000200406-25-000152","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Daniel Pinto elected to JNJ Board effective July 1, 2025; to serve on Audit & Compensation Committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Election of Daniel Pinto, President of JPMorganChase, to J&J Board effective July 1, 2025.","Pinto will serve on Audit Committee and Compensation & Benefits Committee.","He will become Vice Chairman of JPMorganChase from July 1, 2025 until retirement end of 2026.","J&J paid JPMorganChase approx. $39.2M in FY2024 for banking services including M&A advisory.","Pinto will receive standard non-employee director compensation per 2025 Proxy Statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163524,"accession_number":"0000200406-25-000141","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Director D. Adamczyk to retire from JNJ board May 31; shareholders re-elect all 11 nominees and approve Say on Pay","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director D. Adamczyk retiring effective May 31, 2025 to join Goldman Sachs as Partner; no disagreement with management.","All 11 director nominees elected at Annual Meeting on April 24; say-on-pay approved (1.56B for, 142M against).","Shareholders ratified PwC as auditor for 2025 (1.89B for, 141M against).","Two shareholder proposals defeated: golden parachutes vote (92.6M for, 1.61B against) and human rights assessment (188M for, 1.50B against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163523,"accession_number":"0000200406-25-000110","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"JNJ Q1 adj EPS $2.77 (+2.2%), revenue $21.9B; dividend +4.8% to $1.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net earnings $11.0B ($4.54 diluted EPS) vs $3.3B ($1.34), boosted by $7.3B other income.","Adjusted net earnings $6.71B ($2.77 diluted EPS) vs $6.58B ($2.71), up 1.9% operationally.","Worldwide sales $21.89B, up 2.4% reported, 4.2% operational; US +5.9%, International -1.8%.","Innovative Medicine $13.87B (+2.3% reported, +4.2% op); MedTech $8.02B (+2.5% reported, +4.1% op).","Dividend raised 4.8% to $1.30/quarter, payable June 10, 2025; record May 27, 2025; 63rd annual increase."],"consensus_eps_estimate":null,"consensus_eps_actual":4.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":21893000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163522,"accession_number":"0000200406-25-000106","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bankruptcy court denies J&J's Red River Talc prepackaged plan; $7B reserve reversed","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. Bankruptcy Court for Southern District of Texas denied confirmation of Red River Talc LLC's prepackaged plan on March 31, 2025.","Johnson & Johnson will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution.","The decision is a setback in J&J's strategy to resolve talc-related lawsuits through subsidiary bankruptcy.","Press release attached as Exhibit 99.1 details the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181439,"accession_number":"0001193125-25-036773","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Johnson & Johnson completes €4B multi-tranche euro note offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €600M 2.700% Notes due 2029, €700M 3.050% Notes due 2033, and €1B 3.350% Notes due 2037.","Also issued €700M 3.600% Notes due 2045 and €1B 3.700% Notes due 2055.","Total aggregate principal amount of €4 billion across five tranches.","Underwriting agreement with Citigroup, Deutsche Bank, Goldman Sachs and others dated Feb 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181438,"accession_number":"0001193125-25-030851","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Johnson & Johnson completes $5B debt offering across five tranches with coupons from 4.500% to 5.000%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 4.500% notes due 2027, $750M 4.550% notes due 2028, and $1B 4.700% notes due 2030.","Issued $1.25B 4.850% notes due 2032 and $1.25B 5.000% notes due 2035.","Underwriting agreement signed Feb 18 with Citigroup, BofA Securities, and J.P. Morgan as representatives.","Notes sold under existing S-3 shelf registration; closing occurred Feb 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181437,"accession_number":"0000200406-25-000003","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q4 net earnings down 17%, revenue up 5.3% to $22.52B; adjusted EPS $2.04","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $22.52B, +5.3% YoY; net earnings $3.43B, -17% from $4.13B; diluted EPS $1.41.","Adjusted net earnings $4.95B, adjusted EPS $2.04, down 10.9% from $2.29.","Innovative Medicine (ex-COVID) sales $14.33B (+4.8%); MedTech sales $8.19B (+6.7%).","R&D expense rose 18.3% to $5.30B; operating margin contracted to 17.3% from 22.6%.","Full-year sales $88.82B, +4.3% vs $85.16B; ex-COVID sales +5.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":5.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":88821000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181436,"accession_number":"0000200406-25-000007","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K/A","filed_at":"2025-01-22T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Johnson & Johnson files 8-K/A to fix press release format; no impact on numbers","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Amendment aligns format of Reported Sales line in Exhibit 99.1 with newswire press release.","No reported Q4 or Full Year 2024 sales numbers are changed by this update.","Original press release covering period ended December 29, 2024 was issued January 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198243,"accession_number":"0000200406-24-000088","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Johnson & Johnson Q3 sales up 5.2% to $22.5B; GAAP EPS down 34% to $1.11 on higher R&D and other charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide sales $22.47B (+5.2% reported, +6.3% operational); MedTech up 5.8%, Innovative Medicine up 4.9%.","GAAP net earnings from continuing ops $2.69B ($1.11 diluted EPS), down 37.5% YoY; adjusted net earnings $5.88B ($2.42 adjusted EPS), down 13.3%.","R&D expense jumped 43.7% to $4.95B (22.0% of sales); other expense net $1.80B vs $0.50B in prior year.","GAAP effective tax rate 19.3% vs 17.4%; adjusted tax rate 19.3% vs 15.6%.","Discontinued ops had no contribution vs $21.7B in prior year (related to Kenvue separation)."],"consensus_eps_estimate":null,"consensus_eps_actual":4.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":66301000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214359,"accession_number":"0000200406-24-000083","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"J&J subsidiary Red River Talc files Chapter 11 for cosmetic talc settlement, increasing contribution by $1.75B to ~$8B","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Red River Talc LLC filed voluntary prepackaged Chapter 11 in Southern District of Texas.","Approximately 83% of current ovarian cancer claimants support the proposed bankruptcy plan.","Settlement contribution increased by $1.75 billion to a present value of approximately $8 billion.","Aims to resolve all current and future U.S. cosmetic talc claims against Johnson & Johnson."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214358,"accession_number":"0000200406-24-000081","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director D.S. Davis retires from Johnson & Johnson board effective Sept 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["D.S. Davis retired as Director after transitioning Audit Committee Chair duties to D. Adamczyk.","Retirement is for personal reasons, not due to any disagreement with management or operations.","Audit Committee Chair responsibilities successfully transitioned to D. Adamczyk prior to departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214357,"accession_number":"0000200406-24-000079","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Johnson & Johnson CHRO Peter Fasolo to retire effective Oct 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Peter M. Fasolo, EVP and CHRO, will step down from role and Executive Committee on October 1, 2024.","Fasolo will depart the company at the end of 2024; no successor announced in the filing.","Retirement is described as elected, with no mention of dispute or performance issues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214356,"accession_number":"0000200406-24-000071","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"J&J Q2 revenue up 4.3% but GAAP EPS falls 5.9%; adjusted EPS rises 10.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $22.4B, +4.3% YoY; GAAP diluted EPS $1.93, -5.9% YoY; adjusted diluted EPS $2.82, +10.2% YoY.","Innovative Medicine (ex-COVID) revenue $14.3B, +6.5% operational; MedTech revenue $7.96B, +2.2% reported.","GAAP net earnings from continuing ops $4.69B, -12.8% YoY, impacted by $194M IPR&D impairments and prior-year gains.","Adjusted net earnings from continuing ops $6.84B, +1.6% YoY; effective tax rate up to 18.5% from 14.7%.","Share repurchase reduced diluted share count to 2,422M from 2,626M YoY, boosting adjusted EPS growth."],"consensus_eps_estimate":null,"consensus_eps_actual":3.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":43830000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233578,"accession_number":"0001193125-24-142828","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Johnson & Johnson completes $4.0B USD and €2.5B multi-tranche note offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.15B 4.800% notes due 2029, $1.15B 4.900% notes due 2031, $850M 4.950% notes due 2034, $850M 5.250% notes due 2054.","Issued €700M 3.200% notes due 2032, €800M 3.350% notes due 2036, €1.0B 3.550% notes due 2044.","Offerings completed on May 20, 2024 under existing shelf registration; underwriting agreements with J.P. Morgan, BofA, Citi, and others.","Proceeds intended for general corporate purposes (not explicitly stated in filing but typical for such issuances)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233577,"accession_number":"0000200406-24-000053","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Johnson & Johnson fully divests remaining Kenvue stake via debt-for-equity exchange","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 17, 2024, JNJ exchanged its remaining 182.3M Kenvue shares for $3.6B commercial paper, eliminating its Kenvue ownership.","JNJ issued $3.6B commercial paper on May 15, 2024 for general corporate purposes, then used it to complete the exchange.","This completes the separation of Consumer Health business announced in Nov 2021; JNJ no longer holds any Kenvue shares.","The commercial paper was satisfied and discharged upon completion of the exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233576,"accession_number":"0000200406-24-000048","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"JNJ proposes $6.475B talc settlement plan; Q1 GAAP EPS cut to $1.34","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposed plan pays $6.475B present value ($8.4B nominal over 25 years) to resolve all ovarian cancer cosmetic talc claims.","Incremental $2.7B charge; total talc reserve now ~$11B present value ($13.7B nominal) as of Q1 2024.","Previously reported GAAP net earnings reduced from $5.4B to $3.3B; EPS from $2.20 to $1.34 for Q1 2024.","Q1 2024 adjusted EPS of $2.71 unchanged; sales $21.38B (+2.3% YoY).","No impact to mesothelioma, state consumer claims; plan excludes those categories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233575,"accession_number":"0000200406-24-000043","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Johnson & Johnson adopts amended bylaws and holds 2024 annual meeting; all directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended by-laws effective April 25, 2024 updated special meeting rules, universal proxy compliance, proxy access, and indemnification.","Annual meeting elected all 13 director nominees; say-on-pay passed with ~89% of votes cast.","PwC ratified as independent auditor for FY2024 with ~94% approval.","Shareholder proposal on gender-based compensation gaps did not pass; 97% of votes cast against.","Bylaws now specify CEO also serves as President unless Board designates otherwise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233574,"accession_number":"0000200406-24-000031","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"JNJ reports Q1 adjusted EPS $2.71 (+12.4% YoY); declares 4.2% dividend increase to $1.24/quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide sales $21.38B, up 2.3% total (6.0% ex-COVID-19 vaccine); MedTech up 4.5%, Innovative Medicine ex-vaccine up 6.9%","GAAP net earnings from continuing ops $5.35B ($2.20 diluted EPS) vs $0.49B loss in prior year (large litigation charges skewed comparison)","Adjusted net earnings $6.58B, up 3.8%; adjusted diluted EPS $2.71 vs $2.41, +12.4%","Board raises quarterly dividend to $1.24/share (from $1.19), a 4.2% increase; marks 62nd consecutive annual increase","New indicated annual dividend $4.96/share; payable June 4, 2024 to holders of record May 21, 2024"],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":21383000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233573,"accession_number":"0000200406-24-000036","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K/A","filed_at":"2024-04-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Johnson & Johnson corrects FY2024 operational sales guidance midpoint to $88.9B","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Full-year 2024 operational sales guidance midpoint revised to $88.9B from $88.0B due to typo correction.","Amendment No. 1 to Form 8-K filed April 16, 2024 corrects error in prior press release; no other changes.","Press release for Q1 2024 (period ended March 31, 2024) otherwise unchanged; specifics not provided here."],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":21383000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}